Beam Therapeutics Stock Filter Stocks by Fundamentals
| BEAM Stock | USD 17.66 0.00 0.00% |
Fundamental analysis of Beam Therapeutics allows traders to better anticipate movements in Beam Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Beam | Shares Owned by Institutions | Build AI portfolio with Beam Stock |
Beam Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Beam Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Beam Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Beam Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Beam Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Beam Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Beam Therapeutics' value.| Shares | Ubs Group Ag | 2024-12-31 | 1.8 M | Temasek Holdings Ltd. | 2024-12-31 | 1.8 M | Geode Capital Management, Llc | 2024-12-31 | 1.8 M | Kynam Capital Management, Lp | 2024-12-31 | 1.8 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 1.8 M | Hhg Plc | 2025-03-31 | 1.8 M | Dimensional Fund Advisors, Inc. | 2025-03-31 | 1.6 M | Redmile Group, Llc | 2024-12-31 | 1.5 M | Bellevue Group Ag | 2024-12-31 | 1.5 M | Vanguard Group Inc | 2025-03-31 | 8.9 M | Ark Investment Management Llc | 2025-03-31 | 8.5 M |
Beam Fundamentals
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (15.97) % | ||||
| Current Valuation | 737.14 M | ||||
| Shares Outstanding | 100.56 M | ||||
| Shares Owned By Insiders | 1.22 % | ||||
| Shares Owned By Institutions | 97.89 % | ||||
| Number Of Shares Shorted | 19.26 M | ||||
| Price To Earning | 37.48 X | ||||
| Price To Book | 1.60 X | ||||
| Price To Sales | 28.30 X | ||||
| Revenue | 63.52 M | ||||
| Gross Profit | (302.07 M) | ||||
| EBITDA | (383.98 M) | ||||
| Net Income | (376.74 M) | ||||
| Cash And Equivalents | 1.09 B | ||||
| Cash Per Share | 15.90 X | ||||
| Total Debt | 161.43 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 4.64 X | ||||
| Book Value Per Share | 11.52 X | ||||
| Cash Flow From Operations | (347.25 M) | ||||
| Short Ratio | 6.75 X | ||||
| Earnings Per Share | (4.61) X | ||||
| Price To Earnings To Growth | (2.30) X | ||||
| Target Price | 44.4 | ||||
| Number Of Employees | 393 | ||||
| Beta | 2.35 | ||||
| Market Capitalization | 1.8 B | ||||
| Total Asset | 1.1 B | ||||
| Retained Earnings | (1.57 B) | ||||
| Working Capital | 696.08 M | ||||
| Current Asset | 2.89 B | ||||
| Current Liabilities | 706.6 M | ||||
| Net Asset | 1.1 B |
About Beam Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Beam Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Beam Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Beam Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Beam Therapeutics Piotroski F Score and Beam Therapeutics Altman Z Score analysis. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.61) | Revenue Per Share | Quarterly Revenue Growth 0.008 | Return On Assets | Return On Equity |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.